Details for New Drug Application (NDA): 214474

✉ Email this page to a colleague

NDA 214474 describes DEFERASIROX, which is a drug marketed by Alkem Labs Ltd, Amneal, Annora Pharma, Aucta, Cipla, MSN, Norvium Bioscience, Teva Pharms Usa, Actavis Elizabeth, Alembic, Bionpharma, Glenmark Speclt, Sun Pharm, Torrent, Zydus Pharms, Aurobindo Pharma Ltd, Chartwell Rx, Piramal, and Stevens J, and is included in thirty-three NDAs. It is available from twenty suppliers. Additional details are available on the DEFERASIROX profile page.

The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DEFERASIROX	deferasirox	TABLET;ORAL	214474	ANDA	Aurobindo Pharma Limited	59651-410	59651-410-30	30 TABLET, FILM COATED in 1 BOTTLE (59651-410-30)
DEFERASIROX	deferasirox	TABLET;ORAL	214474	ANDA	Aurobindo Pharma Limited	59651-411	59651-411-30	30 TABLET, FILM COATED in 1 BOTTLE (59651-411-30)

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	90MG
Approval Date:	Oct 16, 2023	TE:	AB	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	180MG
Approval Date:	Oct 16, 2023	TE:	AB	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	360MG
Approval Date:	Oct 16, 2023	TE:	AB	RLD:	No

Complete Access Available with Subscription